Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Endologix acquires Surmodics' Pounce thrombectomy system for peripheral artery thrombi removal
Acquisition, vascular disease, medical devices, commercialization - Read more

Gilead Sciences, Yuhan expand API supply partnership with $140M deal through 2027
Manufacturing agreement, small molecule, HIV, supply contract - Read more

Incyte, Genesis expand AI drug discovery pact with $80M upfront, $40M equity, $1B+ potential value
Research collaboration, AI/ML, small molecule, drug discovery, milestone payments, equity investment - Read more

Bristol Myers Squibb, Anthropic partner to deploy Claude AI across drug development operations
AI/ML, drug discovery, R&D, data analytics - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Pfizer advances (PF-07872412) to Ph3 for pediatric pneumococcal disease following positive Ph2 immunogenicity data
Vaccine, infectious disease, pneumococcal disease, conjugate vaccine, paediatric population - Read more

Beam Therapeutics presents Ph1/2 (BEAM-302) data targeting alpha-1 antitrypsin deficiency at ATS 2026 conference
Gene therapy, respiratory disease, base editing, alpha-1 antitrypsin deficiency, AAT protein restoration - Read more

Oncopeptides' Pepaxti (melflufen) Ph2 data supports use in relapsed refractory multiple myeloma patients with renal impairment
Small molecule, cancer, multiple myeloma, renal impairment, melphalan, combination therapy - Read more

BioMarin Pharmaceutical's Voxzogo (vosoritide) meets Ph3 primary endpoint in children with hypochondroplasia, signaling FDA filing
Protein therapy, metabolic, natriuretic peptide, hypochondroplasia, achondroplasia, skeletal dysplasia - Read more

Roivant's Immunovant shares Ph2 data for (IMVT-1402) showing strong response rates in rheumatoid arthritis
Antibody, autoimmune, monoclonal antibody, FcRn inhibitor, rheumatoid arthritis - Read more

Parabilis Medicines files for IPO after raising $800M, targeting "undruggable" oncology proteins
Oncology, peptide drugs, undruggable targets, rare disease, clinical-stage - Read more

Critical Path Institute awards Odylia Therapeutics $250K grant to advance USH1C gene therapy
Gene therapy, rare disease, AAV, ophthalmology, preclinical - Read more

Eli Lilly acquires Engage Bio for up to $202M to expand nonviral DNA delivery platform
Gene therapy, rare disease, strategic, major transaction - Read more

GHO Capital, CBC Group merge to form $21B healthcare investment firm, closing in early 2027
Healthcare investment, strategic, major transaction, financial - Read more

US government taps Mapp Biopharmaceutical to supply experimental Ebola antibody treatment as Central Africa outbreak escalates
Monoclonal antibody, infectious disease, strategic, regulatory - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Richard Pazdur declines FDA commissioner candidacy despite 100+ biotech leaders urging his appointment
Regulatory, oncology, operational, strategic - Read more

FDA issues warning letter to Harbin Jixianglong Biotech over semaglutide import restriction violations
GLP-1 receptor agonist, metabolic disease, regulatory, operational, supply chain - Read more

MaaT Pharma faces likely EMA rejection for GvHD treatment Xervyteg, plans re-examination
Microbiome therapy, GvHD, regulatory, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here